Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients

AIDS

Volumn 15, Issue 12, 2001, Pages 1493-1502

  Frater, Alexander J ^a   Beardall, Alison ^a   Ariyoshi, Koya ^b   Churchill, Duncan ^a   Galpin, Sarah ^a   Clarke, John R ^a   Weber, Jonathan N ^a   McClure, Myra O ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Africa; Antiretroviral therapy; HIV drug resistance mutations; HIV sequence variability; HIV subtypes; Progression

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AFRICA; ARTICLE; CODON; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ANALYSIS; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS TYPING;

AFRICA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035903001     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200108170-00006     Document Type: Article

References (20)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
3. HIV-1 nomenclature proposal
4. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort
5. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D
6. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in brazilian patients failing HAART
7. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe
8. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates
9. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility
10. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
11. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
12. A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001)
13. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
14. pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
15. Protease gene analysis of HIV type 1 non-B subtypes in Spain
16. Polymorphic changes in HIV-1 pol as predictive molecular markers for resistance associated mutations
17. Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor
18. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
19. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance